论文部分内容阅读
以人胃癌细胞BGC 823和人肺癌细胞PG-BE1为对象,研究乙烷硒啉与顺铂的体外联合抗肿瘤作用是否表现为协同增效。MTT法检测乙烷硒啉与顺铂单药及不同联合给药方案对BGC 823及PG-BE1细胞的增殖抑制作用;采用经典的中位效应理论计算不同联合方案时两药的联合指数CI,比较单药与联合时顺铂所需剂量的变化。结果显示,乙烷硒啉与顺铂联合可以产生协同作用。设置不同的给药剂量比例时,最明显的协同作用表现为:在人胃癌细胞BGC 823中,顺铂与乙烷硒啉比例为2:3;在人肺癌细胞PG-BE1中,顺铂与乙烷硒啉比例为1:3。乙烷硒啉与顺铂联合后,明显降低了顺铂的用量,并且随着药物浓度的升高,减量作用逐渐提高,起到了联合增效的作用。
Human gastric cancer cell line BGC 823 and human lung cancer cell line PG-BE1 were used to investigate the synergistic effect of ethaseline and cisplatin in combination with anti-tumor effect in vitro. MTT assay was used to test the inhibitory effect of ethaselen combined with cisplatin alone and different combination regimens on the proliferation of BGC 823 and PG-BE1 cells. The classical median effect theory was used to calculate the combined index (CI) Compare monotherapy with cisplatin required dose changes. The results show that ethaselen combined with cisplatin can produce synergies. The most obvious synergistic effect when setting the dose ratio is as follows: the ratio of cisplatin to ethaselen in human gastric cancer cell line BGC 823 is 2: 3; in human lung cancer cell line PG-BE1, cisplatin and Ethane selenium ratio of 1: 3. The combination of ethaselen and cisplatin significantly reduced the dosage of cisplatin, and with the increase of drug concentration, the decrement gradually increased, playing a synergistic effect.